Fundamental Analysis of VYANT BIO INC(NASDAQ:VYNT) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to VYNT. VYNT was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of VYNT have multiple concerns. VYNT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VYNT has reported negative net income.

In the past year VYNT has reported a negative cash flow from operations.

In the past 5 years VYNT always reported negative net income.

In the past 5 years VYNT always reported negative operating cash flow.

1.2 Ratios

VYNT has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VYNT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VYNT does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, VYNT has more shares outstanding

The number of shares outstanding for VYNT has been increased compared to 5 years ago.

The debt/assets ratio for VYNT is higher compared to a year ago.

2.2 Solvency

VYNT has an Altman-Z score of -11.95. This is a bad value and indicates that VYNT is not financially healthy and even has some risk of bankruptcy.

VYNT has a Altman-Z score of -11.95. This is amonst the worse of the industry: VYNT underperforms 80.35% of its industry peers.

A Debt/Equity ratio of 0.03 indicates that VYNT is not too dependend on debt financing.

The Debt to Equity ratio of VYNT (0.03) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	-11.95

ROIC/WACCN/A

WACC8.02%

2.3 Liquidity

VYNT has a Current Ratio of 3.14. This indicates that VYNT is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 3.14, VYNT is doing worse than 69.89% of the companies in the same industry.

A Quick Ratio of 3.13 indicates that VYNT has no problem at all paying its short term obligations.

VYNT has a Quick ratio of 3.13. This is in the lower half of the industry: VYNT underperforms 68.94% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.14
Quick Ratio	3.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for VYNT have decreased strongly by -101.61% in the last year.

Looking at the last year, VYNT shows a very negative growth in Revenue. The Revenue has decreased by -86.19% in the last year.

VYNT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -53.03% yearly.

EPS 1Y (TTM)-101.61%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-260.59%

Revenue 1Y (TTM)-86.19%

Revenue growth 3Y-55%

Revenue growth 5Y-53.03%

Revenue growth Q2Q-95.99%

3.2 Future

VYNT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.54% yearly.

The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad

EPS Next Y37.93%

EPS Next 2Y19.54%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VYNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year VYNT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VYNT's earnings are expected to grow with 19.54% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.54%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VYNT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VYANT BIO INC

NASDAQ:VYNT (5/12/2023, 7:07:00 PM)

After market: 0.2211 -0.04 (-14.96%)

0.26

-0.08 (-23.51%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.63M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.14
Quick Ratio	3.13
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-101.61%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y37.93%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-86.19%

Revenue growth 3Y-55%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VYANT BIO INC (VYNT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens